The usefulness of in vivo gene expression investigations from peripheral white blood cells:: a preliminary study

被引:7
作者
Ember, I [1 ]
Kiss, I
Raposa, T
机构
[1] Univ Pecs, Sch Med, Inst Prevent Med, Pecs, Hungary
[2] St Istvan Hosp, Dept Internal Med 3, Budapest, Hungary
关键词
cytostatic treatment; gene expression; leukaemia; lymphoma; oncogene; tumour suppressor gene;
D O I
10.1097/00008469-199908000-00010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Alterations of once/tumour suppressor genes are involved in the formation of human hematological malignancies. Previously, in animal models, we demonstrated the applicability of in vivo gene expression investigations to monitor the effects of certain carcinogenic chemicals. In our present study we determined the expression of once/suppressor genes from isolated peripheral white blood cells of patients with chronic myeloid leukaemia (CLL) and non-Hodgkin lymphoma (NHL). Gene expressions were determined by isolation of total RNA and slot blot hybridization with chemiluminescently labeled gene probes (Ha-ras, c-myc and p53) Expression levels were compared before and after treatment with a combined cytostatic protocol, containing cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). Both the CLL and NHL group of patients exhibited significantly higher expression of the investigated genes than healthy controls. One month after the cytostatic treatment, we found considerably fewer individuals with overexpressed oncogenes than before the treatment. Our study proved that once/tumour suppressor gene expressions could be used as biomarkers of certain hematological malignancies, and to monitor the therapeutical effect of cytostatic drugs. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:331 / 334
页数:4
相关论文
共 15 条
[1]   PROTO-ONCOGENE ACTIVATION DURING CHEMICALLY-INDUCED HEPATOCARCINOGENESIS IN RODENTS [J].
BEER, DG ;
PITOT, HC .
MUTATION RESEARCH, 1989, 220 (01) :1-10
[2]  
BOIVIN JF, 1981, JNCI-J NATL CANCER I, V67, P751
[3]  
BOSARI S, 1995, VIRCHOWS ARCH, V427, P229
[4]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[5]  
DEEG HJ, 1984, EXP HEMATOL, V12, P660
[6]  
Ember I, 1998, IN VIVO, V12, P201
[7]  
Ember I, 1998, ANTICANCER RES, V18, P1149
[8]  
Ember I, 1998, IN VIVO, V12, P489
[9]  
EMBER I, 1995, ANTICANCER RES, V15, P1285
[10]  
Ember Istvan, 1995, In Vivo (Attiki), V9, P65